David Westenberg
Stock Analyst at Piper Sandler
(4.16)
# 535
Out of 4,667 analysts
145
Total ratings
51.28%
Success rate
14.11%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKYA Akoya Biosciences | Reiterates: Overweight | $4 → $3 | $2.16 | +38.89% | 7 | Nov 19, 2024 | |
| NTRA Natera | Maintains: Overweight | $150 → $200 | $168.42 | +18.75% | 13 | Nov 18, 2024 | |
| TEM Tempus AI | Reiterates: Neutral | $40 → $70 | $54.88 | +27.55% | 2 | Nov 12, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $2.5 | $1.72 | +45.35% | 6 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Overweight | $195 → $185 | $131.68 | +40.49% | 14 | Nov 11, 2024 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $26 → $22 | $17.28 | +27.31% | 6 | Nov 11, 2024 | |
| EXAS Exact Sciences | Maintains: Overweight | $85 → $75 | $52.70 | +42.31% | 9 | Nov 11, 2024 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8 → $8.5 | $6.13 | +38.66% | 8 | Nov 11, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $6 → $7 | $4.42 | +58.37% | 11 | Nov 11, 2024 | |
| IDXX IDEXX Laboratories | Reiterates: Neutral | $520 → $435 | $413.91 | +5.10% | 9 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $165 | $161.03 | +2.47% | 5 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $240 | $236.79 | +1.36% | 2 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $195 → $210 | $175.45 | +19.69% | 11 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $34 | $30.68 | +10.82% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $14.90 | +17.45% | 9 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $13.44 | +19.05% | 8 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $15.36 | +30.21% | 7 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.75 | +9.09% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $13.32 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $37.48 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $51.82 | - | 1 | Nov 21, 2017 |
Akoya Biosciences
Nov 19, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $2.16
Upside: +38.89%
Natera
Nov 18, 2024
Maintains: Overweight
Price Target: $150 → $200
Current: $168.42
Upside: +18.75%
Tempus AI
Nov 12, 2024
Reiterates: Neutral
Price Target: $40 → $70
Current: $54.88
Upside: +27.55%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Neutral
Price Target: $2 → $2.5
Current: $1.72
Upside: +45.35%
Illumina
Nov 11, 2024
Maintains: Overweight
Price Target: $195 → $185
Current: $131.68
Upside: +40.49%
Fulgent Genetics
Nov 11, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $17.28
Upside: +27.31%
Exact Sciences
Nov 11, 2024
Maintains: Overweight
Price Target: $85 → $75
Current: $52.70
Upside: +42.31%
Cytek Biosciences
Nov 11, 2024
Maintains: Overweight
Price Target: $8 → $8.5
Current: $6.13
Upside: +38.66%
Adaptive Biotechnologies
Nov 11, 2024
Maintains: Overweight
Price Target: $6 → $7
Current: $4.42
Upside: +58.37%
IDEXX Laboratories
Nov 4, 2024
Reiterates: Neutral
Price Target: $520 → $435
Current: $413.91
Upside: +5.10%
Oct 28, 2024
Maintains: Neutral
Price Target: $150 → $165
Current: $161.03
Upside: +2.47%
Oct 28, 2024
Maintains: Neutral
Price Target: $235 → $240
Current: $236.79
Upside: +1.36%
Aug 14, 2024
Maintains: Overweight
Price Target: $195 → $210
Current: $175.45
Upside: +19.69%
Aug 13, 2024
Maintains: Overweight
Price Target: $30 → $34
Current: $30.68
Upside: +10.82%
Aug 6, 2024
Maintains: Neutral
Price Target: $17 → $18
Current: $14.90
Upside: +17.45%
Jul 1, 2024
Maintains: Neutral
Price Target: $19 → $16
Current: $13.44
Upside: +19.05%
Feb 26, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $15.36
Upside: +30.21%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.75
Upside: +9.09%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $13.32
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $37.48
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $51.82
Upside: -